Research Article

*Author for correspondence: Tel.: +86 29 8532 4615; Fax: +86 29 8525 2580;

Second Department of Thoracic Surgery, First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, China

Search for more papers by this author

Weidong Zhao

Department of Oncosurgery, Weinan Central Hospital of Shanxi Province, Weinan, China

Search for more papers by this author

Jia Zhang

Second Department of Thoracic Surgery, First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, China

Search for more papers by this author

Published Online:15 Aug 2017https://doi.org/10.2217/epi-2017-0023

View article

Abstract

Aim: This study aimed to explore the epigenetic modifications of signature genes in lung adenocarcinoma. Materials & methods: The data of miRNA expression, mRNA expression and DNA methylation were downloaded from The Cancer Genome Atlas. Differential analysis was performed, followed by correlation analysis of miRNA–mRNA and DNA methylation-mRNA. Results: A total of 14 significant inverse correlations between gene expression and DNA methylation were identified, the expressions of which were selected for further validation via GSE27262, displaying similar pattern with that of the integrated analysis. In addition, qRT-PCR results showed that the expression profiling results of six mRNAs and one miRNA were consistent with the findings of integrated analysis. Five genes showed higher diagnostic value, which was also associated with overall survival of patients. Conclusion: Taken together, the epigenetic alterations of signature genes may hold promise for becoming biomarkers for the early detection of lung adenocarcinoma.

Keywords:

References

1 Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J. Clin. 61(2), 69–90 (2011).
MedlineGoogle Scholar
2 Molina JR, Yang P, Cassivi SD, Schild SE, Adjei AA. Non-small-cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin. Proc. 83(5), 584–594 (2008).
MedlineGoogle Scholar
3 Tian Z, Wen S, Zhang Y et al. Identification of dysregulated long non-coding RNAs/microRNAs/mRNAs in TNM I stage lung adenocarcinoma. Oncotarget doi:10.18632/oncotarget.18512 (2017) (Epub ahead of print).
Google Scholar
4 Ricordel C, Labalette-Tiercin M, Lespagnol A et al. EFGR-mutant lung adenocarcinoma and Li–Fraumeni syndrome: report of two cases and review of the literature. Lung Cancer 87(1), 80–84 (2015).
MedlineGoogle Scholar
5 Yano T, Haro A, Shikada Y, Maruyama R, Maehara Y. Non-small-cell lung cancer in never smokers as a representative ‘non-smoking-associated lung cancer’: epidemiology and clinical features. Int. J. Clin. Oncol. 16(4), 287–293 (2011).
Medline CASGoogle Scholar
6 Du J, Zhang L. Integrated analysis of DNA methylation and microRNA regulation of the lung adenocarcinoma transcriptome. Oncol. Rep. 34(2), 585–594 (2015).
Medline CASGoogle Scholar
7 Suzuki A, Makinoshima H, Wakaguri H et al. Aberrant transcriptional regulations in cancers: genome, transcriptome and epigenome analysis of lung adenocarcinoma cell lines. Nucleic Acids Res. 42(22), 13557–13572 (2014).
Medline CASGoogle Scholar
8 Yang ZH, Zheng R, Gao Y, Zhang Q, Zhang H. Abnormal gene expression and gene fusion in lung adenocarcinoma with high-throughput RNA sequencing. Cancer Gene Ther. 21(2), 74–82 (2014).
Medline CASGoogle Scholar
9 Seo JS, Ju YS, Lee WC et al. The transcriptional landscape and mutational profile of lung adenocarcinoma. Genome Res. 22(11), 2109–2119 (2012).
Medline CASGoogle Scholar
10 Zhang S, Zhong B, Chen M et al. Epigenetic reprogramming reverses the malignant epigenotype of the MMP/TIMP axis genes in tumor cells. Int. J. Cancer 134(7), 1583–1594 (2014).
Medline CASGoogle Scholar
11 Valdmanis PN, Roy-Chaudhuri B, Kim HK et al. Upregulation of the microRNA cluster at the Dlk1-Dio3 locus in lung adenocarcinoma. Oncogene 34(1), 94–103 (2013).
MedlineGoogle Scholar
12 Johnson SM, Grosshans H, Shingara J et al. RAS is regulated by the let-7 microRNA family. Cell 120(5), 635–647 (2005).
Medline CASGoogle Scholar
13 Heyn H, Esteller M. DNA methylation profiling in the clinic: applications and challenges. Nat. Rev. Genet. 13(10), 679–692 (2012).
Medline CASGoogle Scholar
14 Esteller M. Epigenetics in cancer. N. Engl. J. Med. 358(11), 1148–1159 (2008).
Medline CASGoogle Scholar
15 Esteller M. Epigenetic gene silencing in cancer: the DNA hypermethylome. Hum. Mol. Genet. 16(R1), R50–R59 (2007).
Medline CASGoogle Scholar
16 Robertson KD. DNA methylation and human disease. Nat. Rev. Genet. 6(8), 597–610 (2005).
Medline CASGoogle Scholar
17 Selamat SA, Chung BS, Girard L et al. Genome-scale analysis of DNA methylation in lung adenocarcinoma and integration with mRNA expression. Genome Res. 22(7), 1197–1211 (2012).
Medline CASGoogle Scholar
18 Anders S, Huber W. Differential expression analysis for sequence count data. Genome Biol. 11(10), R106 (2010).
Medline CASGoogle Scholar
19 Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J. R Stat. Soc. Series B (Methodol.) 57(1), 289–300 (1995).
Google Scholar
20 Warden CD, Lee H, Tompkins JD et al. COHCAP: an integrative genomic pipeline for single-nucleotide resolution DNA methylation analysis. Nucleic Acids Res. 41(11), e117 (2013).
Medline CASGoogle Scholar
21 Smoot ME, Ono K, Ruscheinski J, Wang PL, Ideker T. Cytoscape 2.8: new features for data integration and network visualization. Bioinformatics 27(3), 431–432 (2011).
Medline CASGoogle Scholar
22 Young MD, Wakefield MJ, Smyth GK, Oshlack A. Gene ontology analysis for RNA-seq: accounting for selection bias. Genome Biol. 11(2), R14 (2010).
MedlineGoogle Scholar
23 Kanehisa M, Goto S. KEGG: kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 28(1), 27–30 (2000).
Medline CASGoogle Scholar
24 Bustin SA, Benes V, Garson JA et al. The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments. Clin. Chem. 55(4), 611–622 (2009).
Medline CASGoogle Scholar
25 Robin X, Turck N, Hainard A et al. pROC: an open-source package for R and S+ to analyze and compare ROC curves. BMC Bioinformatics 12, 77 (2011).
MedlineGoogle Scholar
26 Saito M, Shiraishi K, Kunitoh H, Takenoshita S, Yokota J, Kohno T. Gene aberrations for precision medicine against lung adenocarcinoma. Cancer Sci. 107(6), 713–720 (2016).
Medline CASGoogle Scholar
27 Krasnov GS, Dmitriev AA, Melnikova NV et al. CrossHub: a tool for multi-way analysis of The Cancer Genome Atlas (TCGA) in the context of gene expression regulation mechanisms. Nucleic Acids Res. 44(7), e62 (2016).
MedlineGoogle Scholar
28 Tiger CF, Fougerousse F, Grundstrom G, Velling T, Gullberg D. Alpha11beta1 integrin is a receptor for interstitial collagens involved in cell migration and collagen reorganization on mesenchymal nonmuscle cells. Dev. Biol. 237(1), 116–129 (2001).
Medline CASGoogle Scholar
29 Wang KK, Liu N, Radulovich N et al. Novel candidate tumor marker genes for lung adenocarcinoma. Oncogene 21(49), 7598–7604 (2002).
Medline CASGoogle Scholar
30 Chong IW, Chang MY, Chang HC et al. Great potential of a panel of multiple hMTH1, SPD, ITGA11 and COL11A1 markers for diagnosis of patients with non-small-cell lung cancer. Oncol. Rep. 16(5), 981–988 (2006).
Medline CASGoogle Scholar
31 Xu JB, Bao Y, Liu X, Liu Y, Huang S, Wang JC. Defective expression of transforming growth factor beta type II receptor (TGFBR2) in the large cell variant of non-small-cell lung carcinoma. Lung Cancer 58(1), 36–43 (2007).
MedlineGoogle Scholar
32 Dmitriev AA, Kashuba VI, Haraldson K et al. Genetic and epigenetic analysis of non-small-cell lung cancer with NotI-microarrays. Epigenetics 7(5), 502–513 (2012).
Medline CASGoogle Scholar
33 Qu H, Zhu M, Tao Y, Zhao Y. Suppression of peripheral myelin protein 22 (PMP22) expression by miR29 inhibits the progression of lung cancer. Neoplasma 62(6), 881–886 (2015).
Medline CASGoogle Scholar
34 Iruela-Arispe ML, Luque A, Lee N. Thrombospondin modules and angiogenesis. Int. J. Biochem. Cell Biol. 36(6), 1070–1078 (2004).
Medline CASGoogle Scholar
35 Lawler J. The functions of thrombospondin-1 and-2. Curr. Opin. Cell Biol. 12(5), 634–640 (2000).
Medline CASGoogle Scholar
36 Chijiwa T, Abe Y, Inoue Y et al. Cancerous, but not stromal, thrombospondin-2 contributes prognosis in pulmonary adenocarcinoma. Oncol. Rep. 22(2), 279–283 (2009).
Medline CASGoogle Scholar
37 Metodieva SN, Nikolova DN, Cherneva RV, Dimova Ii, Petrov DB, Toncheva DI. Expression analysis of angiogenesis-related genes in Bulgarian patients with early-stage non-small-cell lung cancer. Tumori 97(1), 86–94 (2011).
Medline CASGoogle Scholar
38 Tessema M, Yingling CM, Snider AM et al. GATA2 is epigenetically repressed in human and mouse lung tumors and is not requisite for survival of KRAS mutant lung cancer. J. Thorac. Oncol. 9(6), 784–793 (2014).
Medline CASGoogle Scholar
39 Zhang ML, Nie FQ, Sun M et al. HOXA5 indicates poor prognosis and suppresses cell proliferation by regulating p21 expression in non-small-cell lung cancer. Tumour Biol. 36(5), 3521–3531 (2015).
Medline CASGoogle Scholar
40 Kim DS, Kim MJ, Lee JY et al. Epigenetic inactivation of Homeobox A5 gene in non-small-cell lung cancer and its relationship with clinicopathological features. Mol. Carcinog. 48(12), 1109–1115 (2009).
Medline CASGoogle Scholar
41 Huang T, Li J, Zhang C et al. Distinguishing lung adenocarcinoma from lung squamous cell carcinoma by two hypomethylated and three hypermethylated genes: a meta-analysis. PLoS ONE 11(2), e0149088 (2016).
MedlineGoogle Scholar
42 Yin D, Jia Y, Yu Y et al. SOX17 methylation inhibits its antagonism of Wnt signaling pathway in lung cancer. Discov. Med. 14(74), 33–40 (2012).
MedlineGoogle Scholar
43 Li W, Huang K, Guo H, Cui G. Meis1 regulates proliferation of non-small-cell lung cancer cells. J. Thorac. Dis. 6(6), 850–855 (2014).
MedlineGoogle Scholar
44 Rauch TA, Wang Z, Wu X, Kernstine KH, Riggs AD, Pfeifer GP. DNA methylation biomarkers for lung cancer. Tumour Biol. 33(2), 287–296 (2012).
Medline CASGoogle Scholar
45 Waddington CH. The epigenotype. 1942. Int. J. Epidemiol. 41(1), 10–13 (2012).
Medline CASGoogle Scholar

Vol. 9, No. 9

Supplemental Materials

Metrics

Downloaded 151 times

History

Published online 15 August 2017

Published in print September 2017

Information

Keywords

Financial & competing interests disclosure

This study is supported by the Project supported by the Scientific and Technological Planning project of Shaanxi Province (grant no. 2014K11-01-01-22). The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

Writing assistance was utilized in the production of this manuscript.

Ethical conduct of research

The authors state that they have obtained appropriate institutional review board approval or have followed the principles outlined in the Declaration of Helsinki for all human or animal experimental investigations. In addition, for investigations involving human subjects, informed consent has been obtained from the participants involved.

PDF download

Comprehensive epigenetic analysis of the signature genes in lung adenocarcinoma

Abstract

References